Saturday 17 October 2026
Export KRRO’s income statement to Excel — free account
Korro Bio, Inc.
KRRO Healthcare Biotechnology
Korro Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, up 181.5% from fiscal 2024. In the quarter to June 2026, revenue fell 86.3%, EPS grew 61.0% and free cash flow grew 12.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.53
0.78
−8.38%
Follow KRRO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 11.77 | 30.98 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (4.25) | (26.18) | |
P/B ratio |
— | — | 1.46 | 4.54 | |
Price to Tangible BV |
— | — | 1.46 | 4.54 | |
EV/Sales |
— | — | 2.88 | 25.88 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (0.23) | (5.50) | |
EV/FCF |
— | — | (0.23) | (5.35) | |
Quick Ratio |
9.11 | 7.71 | 6.38 | 6.37 | |
Current Ratio |
9.55 | 8.13 | 6.90 | 6.71 | |
Net Debt/EBITDA |
5.83 | 5.68 | 1.51 | 5.11 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.04 | 0.07 | |
Operating CF/Net income |
0.90 | 0.82 | 0.35 | 0.95 | |
Capex/Depreciation |
(0.10) | (0.05) | (0.13) | (0.15) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 919.58% | 1,267.89% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 505.19% | 596.97% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 160.29% | 167.43% | |
Graham Net Nets |
— | — | 0.27 | 0.08 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (155.68%) | (19.65%) | |
Free Cash Flow Yield |
— | — | (105.08%) | (15.62%) | |
Revenue per Share |
0.00 | 0.00 | 0.14 | 0.12 | |
Operating CF per Share |
(0.96) | (1.39) | (1.88) | (1.83) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.02) | |
Free Cash Flow per Share |
(0.97) | (1.39) | (1.89) | (1.85) | |
Cash per Share |
6.53 | 9.83 | 8.00 | 9.85 | |
Shareholders Equity per Share |
5.86 | 10.31 | 5.48 | 10.54 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.86 | 10.31 | 5.48 | 10.54 | |
Free Cash Flow |
(17.03) | (16.09) | (17.79) | (17.35) | |
Working Capital |
108.00 | 105.38 | 70.44 | 83.59 | |
Capital Expenditures |
(0.04) | (0.02) | (0.08) | (0.17) | |
Net Current Asset Value |
60.41 | 56.17 | 20.31 | 35.71 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.07 | 0.16 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 1.33 | 5.41 | |
Average Payables |
4.38 | 3.07 | 2.82 | 4.13 | |
Average Assets |
171.94 | 192.91 | 169.87 | 202.55 | |
Average Common Equity |
109.16 | 129.30 | 105.93 | 139.33 |
Columns are period end dates